3DBio Therapeutics Receives FDA Rare Pediatric Disease Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients
- Friday, December 6, 2019, 7:09
- Finance
- Add a comment
NEW YORK, Dec. 6, 2019 /PRNewswire/ — 3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation for AuriNovo™, an investigational…
About the Author
adminasapcorp has written 39417 stories on this site.